Currently out of the existing stock ratings of Michael Ulz, 124 are a BUY (66.31%), 58 are a HOLD (31.02%), 5 are a SELL (2.67%).

Michael Ulz

Work Performance Price Targets & Ratings Chart

Analyst Michael Ulz, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 56.99% that have a potential upside of 42.83% achieved within 193 days.

Michael Ulz’s has documented 394 price targets and ratings displayed on 49 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on VKTX, Viking Therapeutics at 22-Oct-2025.

Wall Street Analyst Michael Ulz

Analyst best performing recommendations are on KPTI (KARYOPHARM THERAPEUTICS).
The best stock recommendation documented was for KPTI (KARYOPHARM THERAPEUTICS) at 10/9/2025. The price target of $21 was fulfilled within 1 day with a profit of $152.85 (87.92%) receiving and performance score of 879.21.

Average potential price target upside

ALXN Alexion Pharmaceuticals AVRO AVROBIO BMRN Biomarin Pharmaceutical FOLD Amicus Therapeutics IOVA Iovance Biotherapeutics KPTI Karyopharm Therapeutics MRTX Mirati Ther NLNK NewLink Genetics CHRS Coherus BioSciences FATE Fate Therapeutics NRIX Nurix Therapeutics  RARE Ultragenyx ALLK Allakos IGMS IGM Biosciences LUMO Lumos Pharma ISEE IVERIC bio MRSN Mersana Therapeutics BPMC Blueprint Medicines Corp YMAB Y mAbs Therapeutics AKRO Akero Therapeutics ALNY Alnylam Pharmaceuticals ALVR Allovir  CABA Cabaletta Bio IONS Ionis Pharmaceuticals ORIC Oric Pharmaceuticals  XLO Xilio Development JNCE Jounce Therapeutics FRLN Freeline Therapeutics Holdings Plc TSHA Taysha Gene Therapies  VIR Vir Biotechnology ZNTL Zentalis Pharmaceuticals Llc ALPN Alpine Immune Sciences SLN Silence Therapeutics PLC ARWR Arrowhead Pharmaceuticals DYN Dyne Therapeutics  MIRM Mirum Pharmaceuticals VKTX Viking Therapeutics GUTS Fractyl Health, Common Stock THRD Third Harmonic Bio APLS Apellis Pharmaceuticals ARGX argenx NV ADR AVEO AVEO Pharmaceuticals CNST Constellation Pharmaceuticals GNCA Genocea Biosciences HARP Harpoon Therapeutics IDRA Idera Pharmaceuticals PRTK Paratek Pharmaceuticals PRTO Proteon Therapeutics TARA Protara Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$205

$22.5 (12.33%)

4 years 5 months 25 days ago
(04-May-2021)

3/5 (60%)

$35.09 (20.65%)

938

Hold

$173

$-9.5 (-5.21%)

$156

4 years 5 months 27 days ago
(02-May-2021)

14/24 (58.33%)

$2.73 (1.60%)

682

Hold

$190

4 years 6 months 4 days ago
(25-Apr-2021)

9/11 (81.82%)

$34.41 (22.12%)

350

Buy

$175

$-7.5 (-4.11%)

$165

4 years 8 months 26 days ago
(03-Feb-2021)

3/3 (100%)

$19.41 (12.48%)

397

Hold

$166

$-16.5 (-9.04%)

$175

4 years 8 months 26 days ago
(03-Feb-2021)

23/23 (100%)

$10.41 (6.69%)

828

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Michael Ulz is most bullish on?

Potential upside of $67.58 has been obtained for VKTX (VIKING THERAPEUTICS)

Which stock is Michael Ulz is most reserved on?

Potential downside of -$0 has been obtained for SLN (SILENCE THERAPEUTICS PLC)

What Year was the first public recommendation made by Michael Ulz?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?